Sangamo Therapeutics (SGMO) experienced a decline today, closing at $1.17, down 4.12% from the previous close of $1.22. The stock opened at $1.24, reached a high of $1.25, and dipped to a low of $1.12, with trading volume at 5,137,887 shares, about 49.43% of its average. The decline follows broader negative sentiment in the gene editing sector, influenced by Intellia Therapeutics' announcement of a 27% staff layoff and the halting of a clinical program, which impacted related stocks, including SGMO. Additionally, the market is still reacting to Sangamo's recent news from December 30, 2024, regarding Pfizer's decision to end its collaboration on the hemophilia A gene therapy program. This has left investors uncertain about Sangamo's next steps, despite the potential opportunity to advance the program independently or with a new partner.